# Kalaris Therapeutics, Inc.: financial statements, quarterly

KLRS · Nasdaq · CIK 1754068 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/klrs.md) · [Financials](/companies/klrs/financials.md) · [Filings](/companies/klrs/filings.md) · [Insiders](/companies/klrs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/klrs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [34.2](/filings/0000950170-23-058145.md) | [33.4 d](/filings/0000950170-25-035143.md) | [2.0](/filings/0000950170-25-071339.md) | [3.2](/filings/0000950170-25-107979.md) | [36.0](/filings/0001193125-25-277464.md) | [3.9 d](/filings/0001193125-26-110659.md) | [6.0](/filings/0001193125-26-219328.md) | [8.4](/filings/0001193125-26-344532.md) | [9.1](/filings/0001193125-25-277464.md) | [7.2 d](/filings/0001193125-26-110659.md) | [7.6](/filings/0001193125-26-219328.md) | [9.0](/filings/0001193125-26-344532.md) |
| Operating income | $m | [(47.0)](/filings/0000950170-24-125295.md) | [(62.4) d](/filings/0000950170-25-035143.md) | [(2.6)](/filings/0000950170-25-071339.md) | [(4.2)](/filings/0000950170-25-107979.md) | [(37.8)](/filings/0001193125-25-277464.md) | [(7.1) d](/filings/0001193125-26-110659.md) | [(10.4)](/filings/0001193125-26-219328.md) | [(12.3)](/filings/0001193125-26-344532.md) | [(12.7)](/filings/0001193125-25-277464.md) | [(10.8) d](/filings/0001193125-26-110659.md) | [(11.8)](/filings/0001193125-26-219328.md) | [(12.4)](/filings/0001193125-26-344532.md) |
| Interest expense | $m | not reported | not reported | [0.1](/filings/0000950170-25-071339.md) | [0.5](/filings/0000950170-25-107979.md) | [0.8](/filings/0001193125-25-277464.md) | [1.3 d](/filings/0001193125-26-110659.md) | [1.4](/filings/0001193125-26-219328.md) | [0.0](/filings/0001193125-26-344532.md) | [0.0](/filings/0001193125-25-277464.md) | [0.0 d](/filings/0001193125-26-110659.md) | [0.0](/filings/0001193125-26-219328.md) | [0.0](/filings/0001193125-26-344532.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-125295.md) | [(0.1) d](/filings/0000950170-25-035143.md) | [0.0](/filings/0000950170-24-058607.md) | [0.0](/filings/0000950170-24-094380.md) | [0.0](/filings/0000950170-24-125295.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(44.3)](/filings/0000950170-24-125295.md) | [(59.7) d](/filings/0000950170-25-035143.md) | [(3.4)](/filings/0001193125-25-277464.md) | [(5.7)](/filings/0001193125-25-277464.md) | [(38.1)](/filings/0001193125-25-277464.md) | [(22.0) d](/filings/0001193125-26-110659.md) | [(10.2)](/filings/0001193125-26-344532.md) | [(11.4)](/filings/0001193125-26-344532.md) | [(11.9)](/filings/0001193125-25-277464.md) | [(10.0) d](/filings/0001193125-26-110659.md) | [(10.9)](/filings/0001193125-26-344532.md) | [(11.5)](/filings/0001193125-26-344532.md) |
| Diluted EPS | $ per share | [(0.39)](/filings/0000950170-24-125295.md) | not reported | [(2.60)](/filings/0000950170-25-071339.md) | [(4.26)](/filings/0000950170-25-107979.md) | [(28.16)](/filings/0001193125-25-277464.md) | not reported | [(2.52)](/filings/0001193125-26-219328.md) | [(0.61)](/filings/0001193125-26-344532.md) | [(0.64)](/filings/0001193125-25-277464.md) | not reported | [(0.46)](/filings/0001193125-26-219328.md) | [(0.48)](/filings/0001193125-26-344532.md) |
| Basic EPS | $ per share | [(0.39)](/filings/0000950170-24-125295.md) | not reported | [(2.60)](/filings/0000950170-25-071339.md) | [(4.26)](/filings/0000950170-25-107979.md) | [(28.16)](/filings/0001193125-25-277464.md) | not reported | [(2.52)](/filings/0001193125-26-219328.md) | [(0.61)](/filings/0001193125-26-344532.md) | [(0.64)](/filings/0001193125-25-277464.md) | not reported | [(0.46)](/filings/0001193125-26-219328.md) | [(0.48)](/filings/0001193125-26-344532.md) |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [95.6](/filings/0000950170-24-125295.md) | [90.1](/filings/0000950170-25-035143.md) | [5.2](/filings/0000950170-25-071339.md) | [6.2](/filings/0000950170-25-107979.md) | [1.9](/filings/0001193125-25-277464.md) | [1.6](/filings/0001193125-26-110659.md) | [101](/filings/0001193125-26-219328.md) | [88.4](/filings/0001193125-26-344532.md) | [42.4](/filings/0001193125-25-277464.md) | [98.1](/filings/0001193125-26-344532.md) | [34.4](/filings/0001193125-26-219328.md) | [43.2](/filings/0001193125-26-344532.md) |
| Current assets | $m | [220](/filings/0000950170-23-058145.md) | [188](/filings/0000950170-25-035143.md) | [141](/filings/0000950170-24-058607.md) | [130](/filings/0000950170-24-094380.md) | [123](/filings/0000950170-24-125295.md) | [2.6](/filings/0001193125-26-110659.md) | [102](/filings/0000950170-25-071339.md) | [91.7](/filings/0000950170-25-107979.md) | [78.2](/filings/0001193125-25-277464.md) | [119](/filings/0001193125-26-344532.md) | [98.5](/filings/0001193125-26-219328.md) | [95.9](/filings/0001193125-26-344532.md) |
| Total assets | $m | [248](/filings/0000950170-23-058145.md) | [191](/filings/0000950170-25-035143.md) | [144](/filings/0000950170-24-058607.md) | [131](/filings/0000950170-24-094380.md) | [123](/filings/0000950170-24-125295.md) | [6.2](/filings/0001193125-26-110659.md) | [103](/filings/0000950170-25-071339.md) | [92.8](/filings/0000950170-25-107979.md) | [81.2](/filings/0001193125-25-277464.md) | [122](/filings/0001193125-26-344532.md) | [110](/filings/0001193125-26-219328.md) | [99.5](/filings/0001193125-26-344532.md) |
| Current liabilities | $m | [33.1](/filings/0000950170-23-058145.md) | [28.4](/filings/0000950170-25-035143.md) | [7.7](/filings/0000950170-24-058607.md) | [2.4](/filings/0000950170-24-094380.md) | [1.4](/filings/0000950170-24-125295.md) | [24.7](/filings/0001193125-26-110659.md) | [7.1](/filings/0000950170-25-071339.md) | [7.7](/filings/0000950170-25-107979.md) | [6.1](/filings/0001193125-25-277464.md) | [9.7](/filings/0001193125-26-344532.md) | [8.1](/filings/0001193125-26-219328.md) | [8.7](/filings/0001193125-26-344532.md) |
| Total liabilities | $m | [53.0](/filings/0000950170-23-058145.md) | [45.0](/filings/0000950170-25-035143.md) | [23.7](/filings/0000950170-24-058607.md) | [10.7](/filings/0000950170-24-094380.md) | [1.4](/filings/0000950170-24-125295.md) | [56.8](/filings/0001193125-26-110659.md) | [39.2](/filings/0000950170-25-071339.md) | [39.7](/filings/0000950170-25-107979.md) | [39.3](/filings/0001193125-25-277464.md) | [42.9](/filings/0001193125-26-344532.md) | [41.2](/filings/0001193125-26-219328.md) | [41.9](/filings/0001193125-26-344532.md) |
| Shareholders' equity | $m | [195](/filings/0000950170-24-125295.md) | [(45.0)](/filings/0001193125-26-110659.md) | [(47.5)](/filings/0001193125-25-277464.md) | [(51.5)](/filings/0001193125-25-277464.md) | [(89.4)](/filings/0001193125-25-277464.md) | [(96.6)](/filings/0001193125-26-344532.md) | [63.9](/filings/0001193125-26-344532.md) | [53.1](/filings/0001193125-26-344532.md) | [41.9](/filings/0001193125-25-277464.md) | [78.8](/filings/0001193125-26-344532.md) | [68.6](/filings/0001193125-26-344532.md) | [57.7](/filings/0001193125-26-344532.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(34.5) d](/filings/0000950170-24-125295.md) | [(30.7) d](/filings/0000950170-25-035143.md) | [(4.5)](/filings/0000950170-25-071339.md) | [(4.0) d](/filings/0000950170-25-107979.md) | [(4.3) d](/filings/0001193125-25-277464.md) | [(7.9) d](/filings/0001193125-26-110659.md) | [(7.4)](/filings/0001193125-26-219328.md) | [(12.5) d](/filings/0001193125-26-344532.md) | [(11.3) d](/filings/0001193125-25-277464.md) | [(7.1) d](/filings/0001193125-26-110659.md) | [(11.6)](/filings/0001193125-26-219328.md) | [(11.0) d](/filings/0001193125-26-344532.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001193125-26-110659.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [84.9](/filings/0000950170-23-058145.md) | [93.3](/filings/0000950170-24-058607.md) | [94.6](/filings/0000950170-24-094380.md) | [114](/filings/0000950170-24-125295.md) | [1.3](/filings/0000950170-25-071339.md) | [1.3](/filings/0000950170-25-107979.md) | [1.4](/filings/0001193125-25-277464.md) | [4.1](/filings/0001193125-26-219328.md) | [18.7](/filings/0001193125-26-344532.md) | [18.7](/filings/0001193125-25-277464.md) | [23.7](/filings/0001193125-26-219328.md) | [23.8](/filings/0001193125-26-344532.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 23,804,981 at 2026-08-04, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-344532.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.